Please check your internet connection and try again.
# Clobazam (Oral Formulation)
## Overview
Clobazam is a 1,5-benzodiazepine with anticonvulsant properties. It is used as an adjunctive therapy for seizures associated with Lennox-Gastaut syndrome (LGS).
## Primary Indications
* Adjunctive therapy for seizures associated with Lennox-Gastaut syndrome (LGS) in patients 2 years of age and older.
## Adult Dosing
* **Starting Dose:** 5 mg orally twice daily.
* **Titration:** Increase dose by 5 mg to 10 mg every week based on clinical response and tolerability.
* **Maintenance Dose:** Typically 10 mg to 20 mg orally twice daily.
* **Maximum Dose:** 20 mg orally twice daily (40 mg total per day).
## Pediatric Dosing (2 to less than 10 years of age OR weighing less than 30 kg)
* **Starting Dose:** 5 mg orally once daily.
* **Titration:** Increase dose by 2.5 mg to 5 mg every week based on clinical response and tolerability.
* **Maintenance Dose:** Typically 5 mg orally twice daily.
* **Maximum Dose:** 10 mg orally twice daily (20 mg total per day).
*Note: Dosing may vary based on specific protocols and patient factors. Consult institutional guidelines.*
## Dose Adjustments
* **Hepatic Impairment:** Use with caution. No specific dose adjustment recommendations, but consider starting with a lower dose and titrating slowly.
* **Renal Impairment:** Use with caution. No specific dose adjustment recommendations.
## Contraindications
* Known hypersensitivity to clobazam or other benzodiazepines.
## Adverse Effects
* **Common:** Somnolence, decreased appetite, constipation, aggression, irritability, fatigue, vomiting, upper respiratory tract infection, drooling, ataxia, rash.
* **Serious:** Severe skin reactions (e.g., Stevens-Johnson syndrome), respiratory depression, withdrawal symptoms upon abrupt discontinuation, suicidal behavior or ideation, cognitive impairment, dependence.
## Key Drug Interactions
* **CNS Depressants (e.g., alcohol, opioids, other sedatives):** Increased risk of sedation, respiratory depression, and death.
* **CYP2C19 Inhibitors (e.g., fluconazole):** May increase clobazam concentrations. Monitor for increased adverse effects.
* **CYP2C19 Inducers (e.g., rifampin):** May decrease clobazam concentrations. Monitor for reduced efficacy.
* **Other Anticonvulsants:** Clobazam can affect concentrations of other antiepileptic drugs (AEDs); monitor AED levels and for toxicity.
## Monitoring
* Monitor for seizure frequency and severity.
* Assess for signs of sedation, dizziness, and cognitive impairment.
* Monitor for behavioral changes, including aggression and suicidal ideation.
* Evaluate for signs of withdrawal if discontinuing the medication.
* Monitor for severe skin reactions.
## Clinical Pearls
* Clobazam should be tapered gradually when discontinuing to avoid withdrawal symptoms.
* Educate patients and caregivers about the risks of sedation, cognitive impairment, and potential for dependence.
* Due to potential for withdrawal, abrupt discontinuation is not recommended.
* Consider a sleep assessment as somnolence is a common side effect.
***
*Disclaimer: This information is intended for healthcare professionals and does not substitute for professional medical advice. Always verify current prescribing information and guidelines before administering any medication.*
